These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 31242389)

  • 1. Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins.
    Klesmith JR; Su L; Wu L; Schrack IA; Dufort FJ; Birt A; Ambrose C; Hackel BJ; Lobb RR; Rennert PD
    Mol Pharm; 2019 Aug; 16(8):3544-3558. PubMed ID: 31242389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization.
    Leung WH; Gay J; Martin U; Garrett TE; Horton HM; Certo MT; Blazar BR; Morgan RA; Gregory PD; Jarjour J; Astrakhan A
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31039141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Versatile strategy for controlling the specificity and activity of engineered T cells.
    Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.
    Daniyan AF; Brentjens RJ
    J Leukoc Biol; 2016 Dec; 100(6):1255-1264. PubMed ID: 27789538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
    Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
    Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
    Luskin MR; DeAngelo DJ
    Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
    Marcus A; Eshhar Z
    Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fully human CD19-specific chimeric antigen receptors for T-cell therapy.
    Sommermeyer D; Hill T; Shamah SM; Salter AI; Chen Y; Mohler KM; Riddell SR
    Leukemia; 2017 Oct; 31(10):2191-2199. PubMed ID: 28202953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
    Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
    Ambrose C; Su L; Wu L; Dufort FJ; Sanford T; Birt A; Hackel BJ; Hombach A; Abken H; Lobb RR; Rennert PD
    PLoS One; 2021; 16(3):e0247701. PubMed ID: 33735268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
    Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response.
    Baeuerle PA; Ding J; Patel E; Thorausch N; Horton H; Gierut J; Scarfo I; Choudhary R; Kiner O; Krishnamurthy J; Le B; Morath A; Baldeviano GC; Quinn J; Tavares P; Wei Q; Weiler S; Maus MV; Getts D; Schamel WW; Hofmeister R
    Nat Commun; 2019 May; 10(1):2087. PubMed ID: 31064990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia.
    Wu M; Zhang L; Zhang H; Ning J; Tu S; He Y; Li Y
    Cytotherapy; 2019 Jun; 21(6):659-670. PubMed ID: 31031152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
    Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
    Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.